X

Drug Profile

KK 8123

Alternative Names: KK-8123

Latest Information Update: 28 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kyowa Kirin
Class Antibodies
Mechanism of Action Fibroblast growth factor 23 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical X-linked dominant hypophosphataemic rickets

Most Recent Events

05 Aug 2024 Kyowa Kirin plans a phase I/II trial in X-linked dominant hypophosphataemic rickets (In adults) in USA, France, Germany and Spain (SC) in July 2024 (NCT06525636)
30 Jun 2024 Preclinical trials in X-linked dominant hypophosphataemic rickets in Japan (SC) prior to June 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com